Expert consensus on oral corticosteroids stewardship for the treatment of severe asthma in the Middle East and Africa

IF 3.5 3区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Respiratory medicine Pub Date : 2024-05-22 DOI:10.1016/j.rmed.2024.107674

Mona Al-Ahmad , Ashraf Al Zaabi , Ashraf Madkour , Haider Abdulhameed Alqaraghuli , Hajar Al Hayaan , Hassan Mobayed , Majdy Idrees , Nasser Al busaidi , Salah Zeineldine

{"title":"Expert consensus on oral corticosteroids stewardship for the treatment of severe asthma in the Middle East and Africa","authors":"Mona Al-Ahmad , Ashraf Al Zaabi , Ashraf Madkour , Haider Abdulhameed Alqaraghuli , Hajar Al Hayaan , Hassan Mobayed , Majdy Idrees , Nasser Al busaidi , Salah Zeineldine","doi":"10.1016/j.rmed.2024.107674","DOIUrl":null,"url":null,"abstract":"<div><p>In the Middle East and Africa (MEA) region, overuse of oral corticosteroids (OCS) for asthma management, both as burst and maintenance therapy, poses a significant challenge. Gaps in knowledge regarding the need to taper OCS in patients with severe asthma and the use of OCS in comorbid conditions have been noted. OCS stewardship can help attain optimal and effective OCS tapering along with reducing OCS overuse and over-reliance. In this paper, we discuss current practices regarding the use of OCS in asthma, globally and in the MEA region. Expert recommendations for achieving OCS stewardship in the MEA region have also been presented. Regional experts recommend increasing awareness among patients about the consequences of OCS overuse, engaging community pharmacists, and educating primary healthcare professionals about the benefits of prompt appropriate referral. Innovative local referral tools like ReferID can be utilized to refer patients with asthma to specialist care. The experts also endorse a multidisciplinary team approach and accelerating access to newer medicines like biologics to implement OCS stewardship and optimize asthma care in the MEA region.</p></div>","PeriodicalId":21057,"journal":{"name":"Respiratory medicine","volume":null,"pages":null},"PeriodicalIF":3.5000,"publicationDate":"2024-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0954611124001483/pdfft?md5=03033d4e63e410c2d46acc92029cb805&pid=1-s2.0-S0954611124001483-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Respiratory medicine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0954611124001483","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

In the Middle East and Africa (MEA) region, overuse of oral corticosteroids (OCS) for asthma management, both as burst and maintenance therapy, poses a significant challenge. Gaps in knowledge regarding the need to taper OCS in patients with severe asthma and the use of OCS in comorbid conditions have been noted. OCS stewardship can help attain optimal and effective OCS tapering along with reducing OCS overuse and over-reliance. In this paper, we discuss current practices regarding the use of OCS in asthma, globally and in the MEA region. Expert recommendations for achieving OCS stewardship in the MEA region have also been presented. Regional experts recommend increasing awareness among patients about the consequences of OCS overuse, engaging community pharmacists, and educating primary healthcare professionals about the benefits of prompt appropriate referral. Innovative local referral tools like ReferID can be utilized to refer patients with asthma to specialist care. The experts also endorse a multidisciplinary team approach and accelerating access to newer medicines like biologics to implement OCS stewardship and optimize asthma care in the MEA region.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

中东和非洲治疗严重哮喘的口服皮质类固醇管理专家共识》。

在中东和非洲地区（MEA），过度使用口服皮质类固醇（OCS）治疗哮喘（包括爆发治疗和维持治疗）是一项重大挑战。人们对重症哮喘患者是否需要减量使用口服皮质类固醇以及在合并症中使用口服皮质类固醇的认识存在差距。OCS 管理有助于实现最佳和有效的 OCS 减量，同时减少对 OCS 的过度使用和过度依赖。在本文中，我们将讨论全球和中东和非洲地区目前在哮喘中使用 OCS 的做法。此外，还介绍了在中东和非洲地区实现 OCS 管理的专家建议。该地区的专家提高了患者对过度使用 OCS 后果的认识，让社区药剂师参与进来，并向初级医疗保健专业人员宣传及时适当转诊的益处。可利用 ReferID 等创新的本地转诊工具将哮喘患者转诊至专科医生。专家们还赞同采用多学科团队方法，加快生物制剂等新药的使用，以在中东欧地区实施OCS监管，优化哮喘护理。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Respiratory medicine 医学-呼吸系统

CiteScore

7.50

自引率

0.00%

发文量

199

审稿时长

38 days

期刊介绍： Respiratory Medicine is an internationally-renowned journal devoted to the rapid publication of clinically-relevant respiratory medicine research. It combines cutting-edge original research with state-of-the-art reviews dealing with all aspects of respiratory diseases and therapeutic interventions. Topics include adult and paediatric medicine, epidemiology, immunology and cell biology, physiology, occupational disorders, and the role of allergens and pollutants. Respiratory Medicine is increasingly the journal of choice for publication of phased trial work, commenting on effectiveness, dosage and methods of action.